GFPT2 promotes macrophage dysfunction in atherosclerosis via ACADL glycosylation-dependent suppression of ACADL and Arg1

Atherosclerosis (AS) is a chronic inflammatory disease characterized by lipid-laden macrophage foam cell formation and defective efferocytosis. This study aims to investigate the impact of GFPT2 on macrophage function in AS and its underlying mechanisms. We established an AS model using high-fat diet-fed ApoE−/− mice and ox-LDL-treated RAW264.7 and bone marrow-derived macrophages. H&E staining was conducted to examine histopathological changes in the abdominal aorta. Foam cell formation was evaluated by Oil-red-O staining and Dil-ox-LDL uptake, while efferocytosis was measured using apoptotic thymocyte clearance assays. Protein glycosylation was analyzed via PNGase F digestion and site-directed mutagenesis. GFPT2 knockdown and overexpression were performed to assess its functional role. GFPT2 was upregulated in abdominal aortic tissues and peritoneal macrophages from AS mice, as well as ox-LDL-treated macrophages. In vitro, GFPT2 knockdown reduced foam cell formation, enhanced macrophage efferocytosis, suppressed pro-inflammatory responses, and attenuated mitochondrial ROS production. Notably, GFPT2 downregulated ACADL and Arg1 expression by promoting ACADL N-glycosylation. Moreover, GFPT2 disrupted macrophage function in AS models through regulating Arg1. ACADL knockdown suppressed GFPT2 knockdown-improved macrophage function in AS models. Furthermore, GFPT2 knockdown attenuated the ox-LDL-induced activation of NF-κB and STAT2 and suppression of PPARγ expression. In vivo, GFPT2 knockdown improved serum lipid profile, ameliorated plaque burden, enhanced macrophage efferocytosis, and reduced systemic inflammation in AS mice. Our findings revealed a novel GFPT2-ACADL-Arg1 regulatory axis in AS, where GFPT2 suppressed Arg1 expression via promoting ACADL glycosylation, thereby promoting foam cell formation, impairing efferocytosis, and exacerbating inflammation. Moreover, GFPT2 regulated key transcriptional regulators (NF‑κB, STAT2, PPARγ). These results identified GFPT2 as a pivotal regulator of macrophage homeostasis in AS.

Authors

Institutions

Publication Details

Journal
Cellular and Molecular Life Sciences
Published
2026-04-14
DOI
https://doi.org/10.1007/s00018-026-06203-3
Primary Topic
Immune cells in cancer
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

GFPT2 promotes macrophage dysfunction in atherosclerosis via ACADL glycosylation-dependent suppression of ACADL and Arg1

Zefu Zhang, Kun Ke, C. Zhang, LeYe Yan et al.
Cellular and Molecular Life Sciences
Immune cells in cancer
article

GFPT2 promotes macrophage dysfunction in atherosclerosis via ACADL glycosylation-dependent suppression of ACADL and Arg1

Zefu Zhang, Kun Ke, C. Zhang, LeYe Yan, Junqing Lin, Rong Chen, Weizhu Yang
article en

Abstract

Atherosclerosis (AS) is a chronic inflammatory disease characterized by lipid-laden macrophage foam cell formation and defective efferocytosis. This study aims to investigate the impact of GFPT2 on macrophage function in AS and its underlying mechanisms. We established an AS model using high-fat diet-fed ApoE−/− mice and ox-LDL-treated RAW264.7 and bone marrow-derived macrophages. H&E staining was conducted to examine histopathological changes in the abdominal aorta. Foam cell formation was evaluated by Oil-red-O staining and Dil-ox-LDL uptake, while efferocytosis was measured using apoptotic thymocyte clearance assays. Protein glycosylation was analyzed via PNGase F digestion and site-directed mutagenesis. GFPT2 knockdown and overexpression were performed to assess its functional role. GFPT2 was upregulated in abdominal aortic tissues and peritoneal macrophages from AS mice, as well as ox-LDL-treated macrophages. In vitro, GFPT2 knockdown reduced foam cell formation, enhanced macrophage efferocytosis, suppressed pro-inflammatory responses, and attenuated mitochondrial ROS production. Notably, GFPT2 downregulated ACADL and Arg1 expression by promoting ACADL N-glycosylation. Moreover, GFPT2 disrupted macrophage function in AS models through regulating Arg1. ACADL knockdown suppressed GFPT2 knockdown-improved macrophage function in AS models. Furthermore, GFPT2 knockdown attenuated the ox-LDL-induced activation of NF-κB and STAT2 and suppression of PPARγ expression. In vivo, GFPT2 knockdown improved serum lipid profile, ameliorated plaque burden, enhanced macrophage efferocytosis, and reduced systemic inflammation in AS mice. Our findings revealed a novel GFPT2-ACADL-Arg1 regulatory axis in AS, where GFPT2 suppressed Arg1 expression via promoting ACADL glycosylation, thereby promoting foam cell formation, impairing efferocytosis, and exacerbating inflammation. Moreover, GFPT2 regulated key transcriptional regulators (NF‑κB, STAT2, PPARγ). These results identified GFPT2 as a pivotal regulator of macrophage homeostasis in AS.

Cellular and Molecular Life Sciences
Fujian Medical University (CN), Union Hospital (CN)
Openalex Percentile: Top 25%
Immune cells in cancer
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.